May 20, 2024 8:00am EDT Ensysce Biosciences Continues Collaboration to Advance the Clinical Development of Innovative Overdose Protection Platform
Apr 25, 2024 8:00am EDT Ensysce Biosciences’ CEO Dr. Lynn Kirkpatrick Featured in Xtalks Clinical Edge Magazine
Apr 19, 2024 8:00am EDT Ensysce Biosciences' Presentation from the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference Published
Apr 09, 2024 8:00am EDT Ensysce Biosciences to Participate in the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
Mar 15, 2024 8:00am EDT Ensysce Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results
Feb 21, 2024 8:00am EST Ensysce Biosciences Announces Successful Meeting with FDA for PF614-MPAR, a Next Generation Opioid with Overdose Protection
Feb 15, 2024 8:00am EST Ensysce Biosciences Announces Publication of Clinical Bioequivalence Manuscript
Feb 13, 2024 8:00am EST Ensysce Biosciences, Inc. Announces Exercise of Warrants for $4.7 Million Gross Proceeds